Skip to main content

Table 1 Clinical characteristics of type 1 diabetic patients before and after insulin and AHSCT treatments

From: Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus

  Insulin-only group AHSCT group
Insulin-0M Insulin-12M AHSCT-0M AHSCT-12M
Age (years) 20.18 ± 4.02 18.86 ± 1.46
Gender (female/male) 6/4 5/3
BMI (kg/cm2) 18.28 ± 1.39 19.25 ± 1.11
FBG (mmol/L) 6.50 ± 2.01 6.04 ± 1.70 6.26 ± 0.67 5.59 ± 1.40
HbA1c (%)
(mmol/mol)a
12.20 ± 3.50
(109.90 ± 38.42)
7.33 ± 1.42++
(56.63 ± 15.45)
11.49 ± 1.46
(102.00 ± 16.06)
6.80 ± 0.60###
(51.00 ± 6.73)
Anti-GAD (units/ml) 1230.38 (669.43–1957.29) 1200.00 (725.41–1980.02) 943.68 (294.69–2085.04) 150.4* (31.83–1315.52)
Insulin dose (U/kg/day) 0.66 ± 0.30 0.52 ± 0.34 0.61 ± 0.27 0.15 ± 0.15**###
Fasting C-peptide (ng/ml) 0.62 ± 0.25 0.60 ± 0.50 0.71 ± 0.30 1.01 ± 0.23*#
AUCC 4.56 ± 2.50 4.76 ± 1.42 5.93 ± 2.54 9.59 ± 2.98**#
  1. Data presented as mean ± SD or median (95% CI)
  2. AHSCT autologous hematopoietic stem cell transplantation, 0 M at baseline, 12 M at 12 months
  3. # P < 0.05, ### P < 0.001, compared with the AHSCT-0M group
  4. ++ P < 0.01, compared with the Insulin-0M group
  5. *P < 0.05, **P < 0.01, compared with the Insulin-12M group
  6. aHbA1c values were calculated as mmol/mol. The NGSP converter is available online (http://www.ngsp.org/convert1.asp)